CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 79 enrolled
Drug / intervention
Avelumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05431777
NCT05431777N/ACompleted
CompareCT.gov

Retrospective, Multicenter, Observational Study to Evaluate Current Treatment Patterns and Outcomes in Japanese Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With First-line Avelumab Maintenance

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany·observational·Posted Jun 24, 2022·Updated Apr 1, 2025

In Brief

An observational study evaluating Avelumab for Urothelial Carcinoma. Completed, enrolled 79 participants across 16 sites.

Detailed Summary

The purpose of this clinical trial is to learn about the current treatment patterns, safety, and effects of the study medicine (Avelumab) for the treatment of urothelial carcinoma. This study is seeking Japanese participants who: * have urothelial cancer that has spread * are treated with Avelumab for maintenance We will study the experiences of people receiving avelumab. This helps us learn the current treatment patterns, safety, and effects of avelumab. Participants will take part in this study up to 10 months. During this time, they will have no study visits.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsUrothelial Carcinoma
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedJun 24, 2022
Enrollment StartJul 19, 2022
Primary CompletionJan 16, 2023
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.0 years ago

Interventions

Avelumabdrug

As provided in real world setting